NCT01010672 2015-04-30Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)Merck Sharp & Dohme LLCPhase 2 Completed50 enrolled
NCT00093080 2015-02-13Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)Merck Sharp & Dohme LLCPhase 2 Completed216 enrolled